✦ LIBER ✦

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial

✍ Scribed by Gold, Ralf; Giovannoni, Gavin; Selmaj, Krzysztof; Havrdova, Eva; Montalban, Xavier; Radue, Ernst-Wilhelm; Stefoski, Dusan; Robinson, Randy; Riester, Katherine; Rana, Jitesh; Elkins, Jacob; O'Neill, Gilmore

Book ID: 123579821
Publisher: The Lancet
Year: 2013
Tongue: English
Weight: 416 KB
Volume: 381
Category: Article
ISSN: 0140-6736
DOI: 10.1016/S0140-6736(12)62190-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Daclizumab high-yield process in relapsi

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial

✍ Giovannoni, Gavin; Gold, Ralf; Selmaj, Krzysztof; Havrdova, Eva; Montalban, Xavi 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 334 KB

Firategrast for relapsing remitting mult

Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial

✍ David H Miller; Thomas Weber; Richard Grove; Claire Wardell; Joseph Horrigan; Ol 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 267 KB

Randomised double-blind placebo-controll

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

✍ George C Ebers 📂 Article 📅 1998 🏛 The Lancet 🌐 English ⚖ 97 KB

Intravenous immunoglobulin treatment in

Intravenous immunoglobulin treatment in relapsing-remitting multiple sclerosis: A randomized, double-blind multicenter, placebo-controlled trial

✍ A. Achiron; R. Gilad; S. Hassin; Y. Barak; U. Gabbay; I. Ziv; Y. Goldhamer; E. M 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 144 KB

Ocrelizumab in relapsing-remitting multi

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

✍ Ludwig Kappos; David Li; Peter A Calabresi; Paul O'Connor; Amit Bar-Or; Frederik 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 337 KB

Ocrelizumab in relapsing-remitting multi

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

✍ Ludwig Kappos; David Li; Peter A Calabresi; Paul O'Connor; Amit Bar-Or; Frederik 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 337 KB

## Background: B lymphocytes are implicated in the pathogenesis of multiple sclerosis. we aimed to assess efficacy and safety of two dose regimens of the humanised anti-cd20 monoclonal antibody ocrelizumab in patients with relapsing-remitting multiple sclerosis. ## Methods: We did a multicentre,